NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.

This gene-editing tool has been adapted for molecular diagnostics, utilizing Cas proteins to detect specific nucleic acid sequences with high sensitivity. CRISPR-based platforms such as SHERLOCK ...

Results prove that inversions can be generated in plants without causing further unwanted changes in the expression of genetic information.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.A novel ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

The global gene therapy market size was valued at USD 6.30 billion in 2024 and is projected to reach from USD 7.47 billion in ...